Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation

Condition(s) studied

Investigational drug(s) / intervention(s)

not applicable, observational study: Patients undergoing systemic therapy according to international accepted guidelines for the therapy of atopic dermatitis, observational study

Study summary

Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy.

The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.

Eligibility

Primary outcome measure(s)

• Comparison of T-cell inflammatory markers — 1 year
  Identification of at least one pattern recognition profile showing a strong association with responder status to dupilumab therapy

Trial sites (1)

More Charite University, Berlin, Germany trials in Germany

Other trials for the same condition